Aurobindo Pharma Limited — Q3 FY26
Aurobindo Pharma reported Q3 FY26 consolidated revenue of ₹8,646 crore (+8.4% YoY) and EBITDA of ₹1,773 crore (20.5% margin), driven by strong European growth (+27% YoY to ₹2,70...
bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
67%Questions answered2Evaded / deflected12Questions auditedMixedNumbers vs filing
Answered
High priority
Nature of Eugia III inspection observations and any production stoppage.
Asked by Tushar Manudhane, Motilal Oswal
Management directly stated observations are procedural, no stoppage, and confident in response timeline.
Read the exchange
Question
Sir, with respect to UEugia III inspection, if you could share some color in terms of the nature of observations? And secondly, if implementing any measures to address these issues, will this require certain, let's say, temporary stoppage of production or anything of that sort?
Yugandhar Puvvala, CEO
I think, Tushar, we have already clearly mentioned this, stating that these are all procedural observations. There's no stoppage of production, no stoppage of any nature, and these are procedural and technical, and we are very confident of responding within 15 working days to U.S. FDA.
Partial answer
High priority
Trajectory for U.S. injectable sales given Eugia inspection.
Asked by Damayanti Kerai, HSBC Securities
Management gave qualitative optimism but no specific sales trajectory, citing FDA uncertainty.
deferred to FDA decisionno specific trajectory given
Read the exchange
Question
But given we are yet to get full clearance from the FDA, what kind of trajectory we should build for or we should assume for the U.S. injectable sales?
Yugandhar Puvvala, CEO
But ultimately, U.S. FDA has to take a decision in terms of the Warning Letter, so I cannot comment on what exactly they will do. But we feel confident that we will be in a position to respond. And in my view, probably like next year will be, again, same double-digit growth...
Answered
High priority
Update on Lannett FTC approval process and timeline.
Asked by Neha Manpuria, Bank of America
Management gave a clear timeline (Q1 2027) and expressed confidence in progress.
Read the exchange
Question
Could you give us an update on where we are in the approval process from the FTC, and when should we expect the completion of that transaction?
Swami Iyer, CEO
Right now, we are actively engaging with the FTC through our attorneys, and we are very pleased with the progression of the process at up to this point. We feel confident that this process will be completed early in the next fiscal year, that is Q1 of 2027.
Evasive
High priority
EBITDA impact from Pen G facility and when margins improve.
Asked by Neha Manpuria, Bank of America
Management refused to give a specific EBITDA impact, citing market prices and confidentiality.
no specific EBITDA number givendeferred to market prices
Read the exchange
Question
So, sir, you know, roughly, what would have been the EBITDA impact from the Pen G facility in fiscal 2026? And as we think about the 10,000-ton production that you've mentioned over the next year, at what point do you see this actually start reflecting in the gross margins...
Santhanam Subramanian, CFO
While we may not like to specifically talk about the EBITDA numbers, but, it is well known based on the current market price and the import MIP price, et cetera. Even assuming some discount, we could see a better improved, EBITDA in the coming year.
Answered
Medium priority
Pen G production volume and internal utilization this quarter.
Asked by Speaker 16
Management gave a clear answer: fully utilized internally, with annualized production rate.
Read the exchange
Question
Subra, just to follow up, this Pen G sale, for the quarter, how much was produced and was it also sold or fully utilized internally?
Santhanam Subramanian, CFO
I think the last quarter we have fully utilized. We have fully utilized and see, we are now, based on the January production, we are nearly 9,000-10,000 annualized number.
Partial answer
Medium priority
Reason for strong gross margin and sustainability.
Asked by Speaker 16
Management attributed margin improvement to Pen G but gave no quantitative breakdown or sustainability target.
no specific margin breakdownqualitative only
Read the exchange
Question
So what has led to this kind of strong margins, and how sustainable is it?
Santhanam Subramanian, CFO
I think, with the improved performance of the Pen G and the related products, I think, our losses, whatever the losses we have incurred, has come down and which will turn into positive, and this will help.
Evasive
High priority
EBITDA burn from ramp-up businesses and tax rate reason.
Asked by Tarang Agrawal, Old Bridge
Management acknowledged losses but refused to quantify the EBITDA burn.
no specific EBITDA burn number givendeferred to future profitability
Read the exchange
Question
So just wanted to get a sense on what's the EBITDA burn, of all these businesses which are in the ramp-up phase, probably for nine-month FY 2026 or your estimate for FY 2026.
Santhanam Subramanian, CFO
In terms of the EBITDA impact loss, as I told you, we are incurring losses in some of these, which will get translated into profit in the coming quarters. We are not specifically giving any number, but we'll be making profit coming over the period of time.
Partial answer
High priority
Biosimilar milestones and revenue potential by FY27.
Asked by Shyam Srinivas, Citibank
Management gave milestones but no quantitative revenue potential for FY27, only a qualitative inflection year.
no specific revenue guidance for FY27deferred to 2029
Read the exchange
Question
Satakarni, sir, just again on just the biosimilar journey now in the next 12 months, what are some of the milestones, and timing that we need to keep in mind, and, any way to kind of assess, how large this could be for us, over time, maybe fiscal 2027 and, and over time?
Satakarni Makkapati, CEO
I believe, to answer the second part of your question, as I've always stated, 2029 would be the inflection year, for, for biotech. ... we expect to ramp all this up, convert this into some sort of commercial momentum by 2029, which is our inflection year, I believe.
Partial answer
Medium priority
Whether gross margin improvement from Pen G is already in numbers.
Asked by Kunal Dhamesha, Aswan Developers
Management acknowledged the question but gave only directional guidance, no specific margin impact.
no quantification of margin impactqualitative only
Read the exchange
Question
So is it fair to say that some of the gross margin improvement that we are baking in from the internal consumption from our facility is already there in the numbers because we are already getting a lower price import?
Santhanam Subramanian, CFO
Kunal, your question is right, actually. That was the scenario, one month to one and a half months back. But, now the prices have started going up, okay? ... we should be seeing an improvement in the gross margins very clearly going forward, right?
Answered
Medium priority
Lannett settlement liability and impact on acquisition price.
Asked by Sagar Walia, Fidelity International
Management clearly stated Lannett's liability is separate and does not affect the acquisition price.
Read the exchange
Question
One question is with regards to the Lannett acquisition, the settlement amount of the fines by Is it final, or it can increase, and will it get adjusted in the price or not?
Swami Iyer, CEO
The settlement of Lannett is their liability, and Aurobindo is in no way liable, nor does it change the math.
Answered
Medium priority
Impact of rupee depreciation on P&L and gross margins.
Asked by Nitin Agarwal, Bank of America
Management confirmed depreciation impact is already reflected in numbers via average rate translation.
Read the exchange
Question
So there has been a significant depreciation of the rupee against the USD, as well as the euro over the last few months. Are the, our numbers fully reflecting, are already beginning to reflect some of the impact of depreciation, or how should we think about it next year?
Santhanam Subramanian, CFO
It's already started reflecting on the numbers, right? Whatever, whatever sales happening at the end customer, that is, at the Europe level or U.S. level, et cetera, we translate at the average rate for the quarter, right?
Answered
Medium priority
CapEx flow for TheraNym biologics CDMO over next two years.
Asked by Sagar Walia, Fidelity International
Management gave a specific CapEx range for the next two years.
Read the exchange
Question
How much would have come in by now, and how much would come in FY 2027?
Santhanam Subramanian, CFO
Probably, we may be incurring anywhere between INR 80-120 million in the next two years.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| U.S. sales ex-Revlimid grew around 9% overall | 9% | 8.4% | Matches filing |
| Injectable sales grew 17% in the quarter | 17% | 8.4% | Overstated vs filing |
| Gross margin for the quarter is 15.95% | 15.95% | 20.5% | Understated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.